**This webpage was produced as an assignment for an undergraduate course at Davidson College**
Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clinical and Diagnostic Laboratory Immunology 2004; 11(30): 437-445.
Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006; 42: 8-13.
Braun RP, Payne LG, Dong L. Characterization of the IFN-γ T cell responses to immediate early antigens in humans with genital herpes. Virology Journal 2006; 3:54.
Bystricka M and Russ G. Immunity in latent herpes simplex virus infection. Acta virologica 2005; 49: 159-167.
Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, Douglas MW. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 2006; 194(Suppl 1): S11-8.
Da Costa, XJ, Brockman MA, Alicot, E et al. Humoral response to herpes simplex virus is complement-dependent. PNAS 1999; 96(22): 12708-12712.
Dohner K, Wolfstein A, Prank U, Echeverri C, Dujardin D, Vallee R, Sodeik B. Function of dynein and dynactin in herpes simplex virus capsid transport. Mol Biol Cell. 2002; 13(8):2795-809
Friedman HM. Immune evasion by herpes simplex virus type 1, strategies for virus survival. Trans Am Clin Climatol Assoc. 2003; 114: 103-112.
Gesser RM, Valyi-Nagy T, Fraser NW. Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virology 1994; 200(2): 791-5.
Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis. 2007. (epub ahead of print).
Herbst-Kralovetz, MM and Pyles, RB. Toll-like receptors, innate immunity and HSV pathogenesis. Herpes 2006; 13(2): 37-41.
Herold BC, WuDunn D, Soltys N, Spear PG. Glycoprotein C of herpes simplex virus type 1 plays a principle role in the adsorption of virus to cells and in infectivity. J Virol. 1991; 65: 1090-1098.
Hill A, Jugovic P, York I et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530): 411-5.
Janeway, C. Immunobiology. 6th edition. New York: Garland Science Publishing, 2005.
Jenkins FJ and Turner SL. Herpes simplex virus: a tool for neuroscientists. Frontiers in Bioscience 1996; 1: d241-247.
Johnson DC, Frame MC, Ligas MW et al. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J Virol. 1988; 62(4): 1347-54.
Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003;18(5): 593-603.
Khanna KM, Lepisto AJ, Decman V, Hendricks RL. Immune control of herpes simplex virus during latency. Current Opinion in Immunology 2004; 16: 463-469.
Koelle DM, Posavad CM, Barnum GR et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest. 1998; 101(7): 1500-8.
Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. J Infect Dis. 1996;173(1):7-17.
Mikloska Z, Sanna PP, Cunningham AL. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol. 1999; 73(7): 5934-44.
Minagawa H and Yanagi Y. Latent herpes simplex virus-1 infection in SCID mice transferred with immune CD4+T cells: a new model for latency. Arch Virol. 2000; 145(11): 2259-72.
Rajcani J and Durmanova V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol. 2006; 51(2): 67-85.
Schang LM, St Vincent MR, Lacasse JJ. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir Chem Chemother. 2006; 17(6): 293-320.
Seidel-Dugan C, Ponce de Leon M, Friedman HM, et al. C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J Virol 1988; 62(11): 4027-4036.
Smiley, JR. Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase? J Virol. 2004; 78(3): 1063-1068.
Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004; 6(5): 401-10.
Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002 Nov 21;347(21):1652-61
Trgovcich J, Johnson D, Roizman B. Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma134.5 and UL41 genes of herpes simplex virus 1. J Virol. 2002; 76: 6974-6986.
Whitley RJ, Miller RL. Immunologic approach to herpes simplex virus. Viral Immunol. 2001;14(2):111-8.
Back to Home Page
Davidson College Biology Department
Contact email@example.com with questions or comments.